Pieris Pharmaceuticals Inc (NASDAQ:PIRS) saw a large decline in short interest in August. As of August 31st, there was short interest totalling 2,492,106 shares, a decline of 39.2% from the August 15th total of 4,097,736 shares. Based on an average trading volume of 306,916 shares, the short-interest ratio is currently 8.1 days. Approximately 4.7% of the company’s stock are sold short.
Several analysts recently commented on PIRS shares. HC Wainwright set a $12.00 price target on shares of Pieris Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, September 4th. BidaskClub downgraded shares of Pieris Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 15th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Pieris Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $12.33.
Shares of NASDAQ:PIRS traded down $0.08 on Tuesday, reaching $4.97. 204,400 shares of the company were exchanged, compared to its average volume of 621,632. The stock has a market cap of $302.59 million, a PE ratio of -12.43 and a beta of 1.62. Pieris Pharmaceuticals has a 1-year low of $4.43 and a 1-year high of $9.75.
Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its quarterly earnings data on Thursday, August 9th. The biotechnology company reported $0.00 EPS for the quarter, missing the Zacks’ consensus estimate of $0.01 by ($0.01). Pieris Pharmaceuticals had a negative net margin of 22.38% and a negative return on equity of 27.81%. The business had revenue of $11.69 million during the quarter, compared to analyst estimates of $13.46 million. On average, analysts forecast that Pieris Pharmaceuticals will post -0.49 EPS for the current year.
In other news, Director Christopher P. Kiritsy purchased 5,000 shares of the stock in a transaction on Friday, September 14th. The stock was bought at an average price of $5.11 per share, for a total transaction of $25,550.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $51,100. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.07% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Public Employees Retirement System of Ohio purchased a new position in shares of Pieris Pharmaceuticals during the 2nd quarter worth about $110,000. California Public Employees Retirement System purchased a new position in Pieris Pharmaceuticals in the second quarter valued at approximately $179,000. Alpine Global Management LLC raised its holdings in Pieris Pharmaceuticals by 125.0% in the second quarter. Alpine Global Management LLC now owns 45,000 shares of the biotechnology company’s stock valued at $228,000 after buying an additional 25,000 shares during the period. Marshall Wace LLP purchased a new position in Pieris Pharmaceuticals in the second quarter valued at approximately $118,000. Finally, Aquilo Capital Management LLC purchased a new position in Pieris Pharmaceuticals in the second quarter valued at approximately $10,013,000. Institutional investors and hedge funds own 64.93% of the company’s stock.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
See Also: Diversification in Investing